BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial. The DSMB is an independent group of medical experts closely monitoring the Phase I/IIa OpRegen® clinical trial. The approval was based on the continued safety observed throughout the fir